Eurofins to Acquire ViraCor-IBT Laboratories

Eurofins Scientific has signed a definitive agreement to acquire ViraCor-IBT Laboratories, a provider of specialty diagnostic testing, including biologic and molecular testing, from majority owner Ampersand Capital and other shareholders for approximately $255 million, subject to post-closing adjustments.

Eurofins reports that the acquisition will strengthen both its pharmaceutical and genomic service offerings and establish a presence in the specialty clinical testing services for infectious disease, immunology, allergy, HLA, and serology. The transaction also includes retaining VIBT’s 270 employees.

Upon closing of the transaction the company will continue to be known as ViraCor-IBT Laboratories. Completion of the transaction is expected in the next 60 days.